10:06:52 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-08-29 Bokslutskommuniké 2023
2023-05-25 Kvartalsrapport 2023-Q3
2023-05-17 Extra Bolagsstämma 2023
2023-02-23 Kvartalsrapport 2023-Q2
2022-11-24 Ordinarie utdelning SELECT B 0.00 SEK
2022-11-23 Årsstämma 2023
2022-11-16 Kvartalsrapport 2023-Q1
2022-08-30 Bokslutskommuniké 2022
2022-05-24 Kvartalsrapport 2022-Q3
2022-02-24 Kvartalsrapport 2022-Q2
2021-11-25 Ordinarie utdelning SELECT B 0.00 SEK
2021-11-24 Årsstämma 2022
2021-11-18 Kvartalsrapport 2022-Q1
2021-08-31 Bokslutskommuniké 2021
2021-05-25 Kvartalsrapport 2021-Q3
2021-02-26 Kvartalsrapport 2021-Q2
2020-11-27 Kvartalsrapport 2021-Q1
2020-11-26 Årsstämma 2021
2020-11-26 Ordinarie utdelning SELECT B 0.00 SEK
2020-08-27 Bokslutskommuniké 2020
2020-05-20 Kvartalsrapport 2020-Q3
2020-02-20 Kvartalsrapport 2020-Q2
2019-11-21 Ordinarie utdelning SELECT B 0.00 SEK
2019-11-20 Årsstämma 2020
2019-11-07 Kvartalsrapport 2020-Q1
2019-08-29 Bokslutskommuniké 2019

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriLäkemedel & Handel
SelectImmune Pharma är ett läkemedelsbolag. Bolaget ämnar utveckla läkemedelskandidater med fokus på endogena inflammatoriska medel och bakteriemolekyler. Produkterna är inriktade mot att förstärka immunsystemet och används huvudsakligen för behandling av infektionssjukdomar, samt kronisk inflammation. Bolaget grundades år 2017 och innehar störst verksamhet inom den nordiska marknaden.
2022-02-03 13:47:58

The protein drug candidate NlpD, which is being developed by SelectImmune Pharma, needs adequate, large-scale production technology for continued development towards clinical trials. To achieve this goal, SelectImmune Pharma collaborates with the leading international manufacturer Lonza. The production technology has now successfully been transferred as a first step towards larger scale production.

The NlpD protein was first identified in "nice bacteria", which release the protein into human cells where it inhibits the basic protein production machinery, reducing inflammation and excessive immune responses to infection. The findings identify the NlpD protein as a new drug candidate, and the recombinant protein has been used successfully to treat infections in animal models.

The collaboration agreement has allowed the successful transfer of our laboratory scale vector design and expression technology to Lonza and the production method has been reproduced in their facilities. The collaboration with an established producer is essential for developing the drug candidate further towards clinical trials. The produced quantity will be tested for biological activity and structural characteristics. 

"The discovery of NlpD offers new promising therapeutic options for the treatment of infections using immunomodulation," says Dr Ines Ambite, scientific coordinator of the project.

"Developing the best possible manufacturing process for our drug candidate is vital," says Ann Gidner, CEO, SelectImmune Pharma.

For more information, please contact:

Ines Ambite

Research coordinator SelectImmune Pharma AB

Phone: +46 762 08 89 58

E-mail: ines.ambite@med.lu.se

Ann Gidner

CEO SelectImmune Pharma AB

Phone: +46 768 17 14 14

E-mail: ann.gidner@selectImmune.com

This disclosure contains information that SelectImmune is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 03-02-2022 13:48 CET.